Comparison of competitive ligand-binding assay and bioassay formats for the measurement of neutralizing antibodies to protein therapeutics-Reference-Cited by-同舟云学术

Comparison of competitive ligand-binding assay and bioassay formats for the measurement of neutralizing antibodies to protein therapeutics

Published:2011-01 Issue:2 Volume:54 Page:351-358
ISSN:0731-7085
Container-title:Journal of Pharmaceutical and Biomedical Analysis
language:en
Short-container-title:Journal of Pharmaceutical and Biomedical Analysis

Author:

Finco Deborah,Baltrukonis Daniel,Clements-Egan Adrienne,Delaria Kathy,Gunn George R.,Lowe John,Maia Mauricio,Wong Teresa

Publisher

Elsevier BV

Subject

Clinical Biochemistry,Spectroscopy,Drug Discovery,Pharmaceutical Science,Analytical Chemistry

Reference22 articles.

1. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products;Koren;J. Immunol. Meth.,2008

2. Immunogenicity of biologically-derived therapeutics: Assessment and interpretation of nonclinical safety studies;Ponce;Regul. Toxicol. Pharmacol.,2009

3. Foundation review: nonclinical development of biopharmaceuticals;Baumann;Drug Discov. Today,2009

4. Pure red cell aplasia and anti-erythropoietin antibodies against human erythropoietin in patients treated with recombinant erythropoietin;Casadevall;New Engl. J. Med.,2002

5. A risk-based approach to immunogenicity concerns of therapeutic protein products – Part 1 – considering consequences of the immune response to a protein;Rosenberg;Biopharm. Int.,2004

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunogenicity of Therapeutic Proteins;Pharmaceutical Biotechnology;2024

2. A competitive ligand binding assay for detection of neutralizing antibodies against an insulin analog;Journal of Immunological Methods;2023-12

3. Neutralizing Antibody Validation Testing and Reporting Harmonization;The AAPS Journal;2023-07-08

4. Bioanalytical Scheme for Antidrug Neutralizing Antibody Assays;Bioanalytical Aspects in Biological Therapeutics;2022-07

5. Pharmacokinetics, safety, tolerability, and immunogenicity of FKB238, a new biosimilar of bevacizumab, in healthy participants;Int. Journal of Clinical Pharmacology and Therapeutics;2022-06-01